AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05455346 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Maximal 60 m Sprint
Description: Following a standardized warm-up, inertial measurement units (IMUs) will be placed on the sternum, sacrum, and bilaterally on the thighs, legs, and foot. Each participant will perform a total of 3 maximal 60 m sprints from a standing position with 1.5-3 min rest in between each trial to minimize the effects of fatigue.
Study NCT05455346 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maximal 60 m Sprint
Description: Following a standardized warm-up, inertial measurement units (IMUs) will be placed on the sternum, sacrum, and bilaterally on the thighs, legs, and foot. Each participant will perform a total of 3 maximal 60 m sprints from a standing position with 1.5-3 min rest in between each trial to minimize the effects of fatigue.
Study NCT05455346 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Romanian Deadlift
Description: The RDL intervention will be performed twice per week for 6 weeks. Participants will hinge at the hips lowering the bar to just below their patella before reversing the movement. The RDL will be performed with a 6 second eccentric component and returning to the start position with a maximal concentric hip extension.
Study NCT05455346 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nordic hamstring exercise
Description: The NHE will be performed twice per week for 6 weeks. Participants will be instructed to maintain their ankles in a dorsiflexed position, lower themselves as close to the ground as possible at a constant and controlled speed while maintaining a neutral position of the hips and trunk, and to cross their arms in front of their chest.
Study NCT06631989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WSD0922-FU
Description: Procedure: Biospecimen Collection - blood samples Undergo collection of blood samples~Procedure: Computed Tomography and/or Magnetic Resonance Imaging Undergo CT and/or MRI~Drug: WSD0922-FU Given PO
Study NCT06631963 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Emotional Awareness and Expression Therapy
Description: Emotional Awareness and Expression Therapy (EAET) is a form of psychotherapy designed to help individuals identify, process, and express emotions that may be linked to physical symptoms or chronic pain. It emphasizes the role of unresolved emotional experiences, such as trauma or interpersonal conflicts, in contributing to physical distress. Through EAET, patients learn to connect their emotions to their physical symptoms, express those emotions in a healthier way, and ultimately reduce both emotional and physical suffering. This therapy has been shown to be effective in treating conditions such as chronic pain, irritable bowel syndrome, and fibromyalgia.
Study NCT06630208 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial release
Description: The experimental group will undergo a 5-day consecutive myofascial release treatment, administered as Osteopathic Manipulative Treatment (OMT), with each session lasting a maximum of 15 minutes. The treatment will consist of three phases targeting the entire mediastinum: Thoracic Inlet (Indirect) Myofascial Release, Rib Raising with continued stretch of the paraspinal muscles to the L2 vertebral level, and Soft Tissue Cervical Paraspinal Muscle Stretch with Suboccipital Muscle Release. Participants will be positioned in a supine posture to enhance diaphragmatic excursion, with each session following a fixed, prearranged sequence of these techniques.
Study NCT06630208 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing exercises
Description: Following the 3 phases of myofascial release, breathing exercises will be done for patients.
Study NCT06630208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pharmacological treatment
Description: Patients will take pharmacological treatment prescribed by the cardiologist.
Study NCT06630208 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological treatment
Description: Patients will take pharmacological treatment prescribed by the cardiologist.
Study NCT05349864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07284890 Treatment A
Description: PF-07284890 tablet by mouth while fasting
Study NCT05349864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07284890 Treatment B
Description: PF-07284890 tablet after low fat meal
Study NCT05349864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07284890 Treatment C
Description: PF-07284890 tablet after high fat meal
Study NCT04286022 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Speed Loss 20% Strength Training
Description: Strength training based on the control of speed loss in execution.
Study NCT04286022 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduced Rest Time Strength Training
Description: Strength training based on a protocol that includes reduced rest times between sets.
Study NCT06565091 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Measurements of physiological parameters of the anterior chamber
Description: Acquisition by the investigational device
Study NCT04763356 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Symptom Care at Home with NP follow up
Description: In the SCH-NP group all participants will report their CIPN related symptoms daily via the app, website or phone tree. Any concerning symptoms will trigger a call back from a nurse practitioner who will use a consensus and evidence based algorithm to prescribe therapies for the CIPN symptoms.
Study NCT06565091 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Measurements of the Axial biometry
Description: Acquisition by the investigational device
Study NCT06526234 — intervention group
Intervention type: DEVICE
Intervention: MRI
Description: MR enterography
Study NCT06357572 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Thrombin generation assay (EnzySystem HemA version A - whole blood)
Description: Whole blood obtained by venipuncture is immediately tested with the EnzySystem HemA version A), before and 0, 30, 120 and 240 minutes after administration of FEIBA.
Study NCT06357572 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Thrombin generation assay (Ceveron s100 (Technoclone) - fresh plasma)
Description: Whole blood is centrifuged to obtain plasma. The fresh plasma is tested using the Ceveron s100.
Study NCT06357572 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Additional coagulation tests
Description: Plasma samples are frozen for later coagulation testing. The following tests are performed:~Factor VIII activity von Willebrand Factor antigen levels von Willebrand Factor ristocetin activity levels Prothrombin Fragment 1+2 levels ADAMTS13 activity FVIII antigen levels Nijmegen Hemostasis Assay
Study NCT06342804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4-MUST, 2 tablets, fasted
Description: 2 tablets (256 mg), fasted
Study NCT05312541 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: pre emptive local anaesthetic wound infiltration
Description: Before skin incision by 15 min the surgeon will infiltrate the wound by syringe containing 20 ml mixture of (10 ml xylocaine 2%and 10 ml bupivacaine 0. 5%) in both groups
Study NCT05312541 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pre emptive local anaesthetic wound infiltration
Description: Before skin incision by 15 min the surgeon will infiltrate the wound by syringe containing 20 ml mixture of (10 ml xylocaine 2%and 10 ml bupivacaine 0. 5%) in both groups
Study NCT04570475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Participants will receive vitamin D+multivitamin for 3 weeks. At the end of 3 weeks they will complete an online or paper questionnaire and blood work will be done.
Study NCT04570475 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: multivitamin
Description: Participants will receive placebo+multivitamin or vitamin D+multivitamin for 3 weeks. At the end of 3 weeks they will complete an online or paper questionnaire and blood work will be done.
Study NCT04570475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: multivitamin
Description: Participants will receive placebo+multivitamin or vitamin D+multivitamin for 3 weeks. At the end of 3 weeks they will complete an online or paper questionnaire and blood work will be done.
Study NCT04570475 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo+multivitamin for 3 weeks. At the end of 3 weeks they will complete an online or paper questionnaire and blood work will be done.
Study NCT06053788 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PocDoc
Description: Point of care digital lipid test
Study NCT05759585 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: person-centered lifestyle intervention
Description: Lifestyle intervention is a combined approach that encourages individuals to change their lifestyles by increasing participation in meaningful readings. This program aims to facilitate the individual's self-development of healthy routines and habits; It includes techniques such as patient education, occupational self-analysis, problem-solving, motivation generation, and implementation of behaviors to prevent and manage disease-related symptoms.
Study NCT06342804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4-MUST, 2 tablets, after meals
Description: 2 tablets (256 mg), after meals
Study NCT05128747 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DASH diet
Description: it will be face to face about the role of nutritional program to control dyslipidemia
Study NCT05478317 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ECL- mPZ
Description: Flapless Technique using Piezoelectric (PZ):~Gingivectomy and intra-sulcular incision will be carried out to remove strip of outlined marginal gingiva. However, no flap will be reflected the osseous recontouring will be carried using special piezoelectric tip below gingival margin. The required distance between the bone crest and the gingival margin will be checked by inserting a periodontal probe into the incision below gingival margin.
Study NCT05478317 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ECL-OF
Description: Open Flap Technique (OF):~Gingivectomy and intra-sulcular incision will be carried out to remove strip of outlined marginal gingiva. Full mucoperiosteal flap will be elevated to preform ostectomy and/or osteoplasty until the desired distance achieved between the bone crest and the gingival margin. After achieving the new supracrestal distance, the flap will be sutured.
Study NCT04756531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07321332 Dose 1
Description: PF-07321332 Dose 1 or Placebo
Study NCT04756531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07321332 Dose 2
Description: PF-07321332 Dose 2 or Placebo
Study NCT04756531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07321332 Dose 3
Description: PF-07321332 Dose 3 or Placebo
Study NCT04756531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07321332 Dose 4
Description: PF-07321332 Dose 4 or Placebo
Study NCT04756531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07321332 Dose 5
Description: PF-07321332 Dose 5 or Placebo
Study NCT04756531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07321332 Dose 4 or Placebo (Fed)
Description: PF-07321332 Dose 5 or Placebo with high fat meal
Study NCT04952714 — intervention group
Intervention type: DEVICE
Intervention: Oxiris
Description: Through a previously established and standardized management protocol, the treating team will prescribe renal replacement therapy by hemodiafiltration (CVVHDF) in the PrismaFlex device, at a dose of 25 mL / Kg of PrismaSate dialysis solutio and the removal filter oXiris® cytokines (Baxter) vs. the standard filter.
Study NCT05639725 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: maxillary Ist premolar extraction
Description: Procedure/Surgery: Patients will undergo bilateral maxillary 1st premolars extraction before bonding followed by leveling \& alignment.
Study NCT05639725 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SURGICAL
Description: Surgery:After leveling and alignment,placement of zygomatic miniplates in bilaterally
Study NCT05652881 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Joint Lavage
Description: An arthrotomy will be made at the time of temporary external fixation and 1L normal saline will be used to irrigate the ankle joint.
Study NCT04732143 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: At least 2 weeks prior to surgery, participants will be given a Vyaire incentive spirometer device and provided with formal training on proper inspiratory muscle breathing exercise using the device. They will be instructed to perform 4 sets of these exercises per day for 14 days prior to surgery.
Study NCT05231304 — intervention group
Intervention type: PROCEDURE
Intervention: Total Talus Replacement (TTR)
Description: Surgical implantation of restor3d's patient-specific custom Total Talus Replacement device.
Study NCT05231304 — intervention group
Intervention type: PROCEDURE
Intervention: Total Ankle Total Talus Replacement (TATTR)
Description: Surgical implantation of restor3d's patient-specific custom Total Ankle Total Talus Replacement (TATTR) device.
Study NCT05231304 — intervention group
Intervention type: PROCEDURE
Intervention: Total Ankle Total Talus Replacement + Subtalar Fusion (TATTR + STJ)
Description: Surgical implantation of restor3d's patient-specific custom Total Ankle Total Talus Replacement (TATTR) device with concurrent subtalar fusion.
Study NCT05231304 — intervention group
Intervention type: PROCEDURE
Intervention: Total Talus Replacement + Subtalar Fusion (TTR + STJ)
Description: Surgical implantation of restor3d's patient-specific custom Total Talus Replacement (TTR) device with concurrent subtalar fusion.
Study NCT06445231 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Implementation of echocardiography in nursing homes
Description: An ultrasound will be carried out in the EHPAD, the result of which will be interpreted by a cardiologist then sent to the establishment and the attending physician with instructions to follow.
Study NCT05954169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR4640
Description: SHR4640 single-dose
Study NCT04300335 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individual Exercise
Description: Supervised body weight \& resistance band resistance exercises in a one-on-one personal training setting plus home based aerobic exercise
Study NCT04300335 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group Exercise
Description: Supervised body weight \& resistance band resistance exercises in a Group setting plus home based aerobic exercise
Study NCT05167253 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-612
Description: UB-612 includes a designer S1-RBD-sFc fusion protein formulated with designer Th and CTL epitope peptides selected from immunodominant M, S2 and N regions known to bind to human MHC I and II.
Study NCT06305429 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HabitE (effective parenting habit) program (in Brazilian Portuguese)
Description: Parents who enroll in the program will receive a series of 6 videos (\~ 7 minutes each), 1 video at a time, generally every 3 days. They will also receive daily written texts, which include implementation tips and an assessment of a target (transition) behavior.
Study NCT06600971 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupressure application
Description: The patients in the experimental group received acupressure application for a total of 8 sessions, 2 sessions per week.
Study NCT06214468 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Acetaminophen and Nicotinamide Riboside
Description: Collection of urine at different time intervals following ingestion of Tylenol plus Nicotinamide Riboside
Study NCT06214468 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Collection of urine at different time intervals following ingestion of Tylenol only
Study NCT06214468 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Acetaminophen
Description: Collection of urine at different time intervals following ingestion of Tylenol only
Study NCT06602011 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: TACE, Lenvatinib, combined with Tislelizumab group
Description: TACE, Lenvatinib \[8mg(\<60kg)/12mg(>60kg) orally daily\] combination with Tislelizumab (200mg administered intravenous injection on Day 1 of each 21-day cycle). After the triple therapy, surgical resection is an option if assessed by the investigator to be feasible, or continued until disease progression or intolerable if not.
Study NCT04810624 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relapse Prevention and Changing Habits (REACH+)
Description: Psychotherapy
Study NCT05392738 — intervention group
Intervention type: DEVICE
Intervention: I-Stent implantation
Description: I-Stent implantation
Study NCT06502769 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Therapeutic Exercise
Description: A therapeutic exercise program will be carried out
Study NCT06502769 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Exercise
Description: A therapeutic exercise program will be carried out
Study NCT06502769 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Neurophysiology Education
Description: A PNE program will be carried out
Study NCT04712578 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeinated pre-workout supplement
Description: The intervention will consist of consuming a standardized meal followed by one serving of the commercially available Pulse caffeinated pre-workout supplement (Legion Athletics, Inc.).
Study NCT04712578 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Non-caffeinated pre-workout supplement
Description: The intervention will consist of consuming a standardized meal followed by one serving of the commercially available Pulse non-caffeinated pre-workout supplement (Legion Athletics, Inc.).
Study NCT04712578 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The intervention will consist of consuming a standardized meal followed by a placebo beverage.
Study NCT05429723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10383
Description: HS-10383 administered as one 50 mg, 150 mg, 450 mg and 900 mg tablet once daily, depending upon randomization.
Study NCT05429723 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HS-10383 Placebo
Description: Placebo for HS-10383
Study NCT05794516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZB004
Description: ZB004 single doses administered subcutaneously as solution
Study NCT05794516 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo single doses administered subcutaneously as solution
Study NCT05218135 — intervention group
Intervention type: OTHER
Intervention: Intervention
Description: Learning session 1: explain key interventions, explain BIC methodology, retrospective patient record analysis Learning session 2: feedback report, share best practices, discussion, set priorities, teaching and improvement, retrospective patient record analysis Learning session 3: feedback report, share best practices, discussion, set priorities, teaching and improvement, retrospective patient record analysis Learning session 4: feedback report
Study NCT06553339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral HS-10516
Description: Oral HIF-2α inhibitor
Study NCT05160077 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Multispectral optoacoustic tomography (MSOT)
Description: MSOT Acuity Echo, iThera medical, Munich
Study NCT06389500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: Adebrelimab, IV
Study NCT06389500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib, PO
Study NCT06389500 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatic Arterial Infusion Chemotherapy
Description: GC regimen±5-FU
Study NCT04922216 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core
Description: Behavioral weight loss core includes behavioral lessons, activity tracker, daily self-weighing, weekly tailored feedback summary.
Study NCT05602116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adipose tissue derived mesenchymal stromal/stem cells (Cell2Cure®)
Description: The Investigational Product is a C2C_ASC cell product (Cell2Cure®, Cell2Cure Aps, Denmark).~C2C_ASC is an advanced therapy investigational medicinal product (ATIMP) manufactured from abdominal adipose tissue derived mesenchymal stromal cells (ASC) from healthy donors. C2C_ASC is aseptically procured and manufactured according to tissue law and GMP by Cell2Cure ApS or Cardiology Stem Cell Center, Rigshospitalet, Copenhagen, Denmark, using manual isolation of cells from abdominal fat tissue, xeno-free cell expansion in automated closed bioreactor systems and cryopreservation of the final product.~The active substance is the in vitro expanded ASCs. The final product, C2C_ASC, is provided as a cryopreserved suspension of 50 million ASCs per ml with a total volume of 1,3 ml per vial. The excipient is CryoStor10 (Biolife Solutions), holding 10% DMSO.
Study NCT05302219 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory rate
Description: The participant alternates respiratory rates of 30, 15 and 7.5 breaths/min. Breathe each frequency for 2 minutes with a one-minute break.